Holen Sie sich die Stockscreener-App
10.71
2.01%
-0.22
Schlusskurs vom Vortag:
$10.93
Offen:
$11.19
24-Stunden-Volumen:
234.20K
Relative Volume:
0.67
Marktkapitalisierung:
$65.51M
Einnahmen:
$55.54M
Nettoeinkommen (Verlust:
$-180.40M
KGV:
-13.60
EPS:
-0.7877
Netto-Cashflow:
$-170.32M
1W Leistung:
-2.10%
1M Leistung:
-22.48%
6M Leistung:
-63.82%
1J Leistung:
-94.60%
1-Tages-Spanne:
$10.19
$11.19
1-Wochen-Bereich:
$10.19
$12.46
52-Wochen-Spanne:
$9.104
$309.60
Gossamer Bio Inc Stock (GOSS) Company Profile
Firmenname
Gossamer Bio Inc
Sektor
Branche
Telefon
(858) 684-1300
Adresse
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
10.71 | 66.91M | 55.54M | -180.40M | -170.32M | -0.7877 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-02-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2025-07-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-05 | Fortgesetzt | Wedbush | Outperform |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-03-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Eingeleitet | Guggenheim | Neutral |
| 2022-12-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Neutral |
| 2022-09-19 | Eingeleitet | Wedbush | Outperform |
| 2022-04-18 | Eingeleitet | Raymond James | Outperform |
| 2022-04-06 | Eingeleitet | UBS | Buy |
| 2022-01-10 | Hochstufung | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-30 | Eingeleitet | Berenberg | Buy |
| 2019-03-05 | Eingeleitet | Barclays | Overweight |
| 2019-03-05 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-05 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-05 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Gossamer Bio Inc (GOSS) Stock Price Target & Forecast - TradingKey
A shareholder falls below 5% in Gossamer Bio (GOSS) after a reverse stock split. - Stock Titan
Gossamer Bio regains Nasdaq compliance after 1-for-80 reverse stock split - TradingView
Form 4 Gossamer Bio Inc For: 25 September By Investing.com - Investing.com Nigeria
GOSSAMER BIO INC (GOSS) Stock Chart - ChartMill
At $10.99 a share, Gossamer Bio (GOSS) director Sandra Milligan receives a stock option. - Stock Titan
At Gossamer Bio (GOSS), director Daniel Thomas O's options carry a $10.99 exercise price. - Stock Titan
Gossamer Bio (GOSS) grants a director options priced at $10.99 per share - Stock Titan
At Gossamer Bio (GOSS), director Drynan Skye receives stock options priced at $10.99 per share. - Stock Titan
Director Russell J. Cox receives Gossamer Bio (GOSS) options with a $10.99-per-share exercise price. - Stock Titan
Gossamer Bio grants director options on 10,000 shares - Stock Titan
Gossamer Bio stock falls 5.99 percent after FDA filing - AD HOC NEWS
Gossamer Bio submits seralutinib NDA after Phase 3 endpoint miss - Mugglehead Investment Magazine
Gossamer Bio Submits First NDA for Seralutinib to FDA for Pulmonary Arterial Hypertension - Kalkine Media
Gossamer Bio (GOSS) Files NDA for Seralutinib Amidst Challenging Valuation Landscape - GuruFocus
Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension - TradingView
Gossamer Bio stock rises on FDA filing for PAH drug - Investing.com India
Gossamer Bio Files New Drug Application for Seralutinib - Yahoo Finance
Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension - TradingView
Gossamer Bio stock rises on FDA filing for PAH drug By Investing.com - Investing.com Nigeria
Gossamer Bio submits NDA for seralutinib in PAH treatment By Investing.com - Investing.com Australia
Gossamer Bio (GOSS) Files NDA for Seralutinib Amid Low Valuation and Mixed Financial Signals - GuruFocus
Gossamer Bio submits NDA for seralutinib in PAH treatment - Investing.com
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension - Yahoo Finance
Gossamer Bio : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Gossamer Bio stock gains 12.04 percent in the latest quote - AD HOC NEWS
Equity in earnings of Gossamer Bio, Inc. – SWB:4GB0 - TradingView
Total assets of Gossamer Bio, Inc. – SWB:4GB0 - TradingView
GOSS Maintained by HC Wainwright & Co. -- Price Target Raised to $90 - GuruFocus
GOSS Price Target Soars to $90 After Reverse Split; Market Prici - GuruFocus
H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
HC Wainwright & Co. maintains Buy rating on Gossamer Bio, $90 price target - TradingView
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Cash flow from financing activities of Gossamer Bio, Inc. – MUN:4GB0 - TradingView
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio Adds Veteran Investor to Board of Directors - The Globe and Mail
Gossamer Bio (NASDAQ: GOSS) Schedules October 27 Vote on Warrants and Preferred Stock Conversion - kalkinemedia.com
Cash flow from financing activities of Gossamer Bio, Inc. – LSX:A42M0V - TradingView
Total assets of Gossamer Bio, Inc. – LSX:A42M0V - TradingView
Gossamer Bio appoints Greg Ciongoli to board of directors By Investing.com - Investing.com Nigeria
Gossamer Bio appoints Greg Ciongoli to board of directors - Investing.com
Gossamer Bio, Inc. Announces Appointment of Greg Ciongoli to Board of Directors and Audit Committee, Effective September 16, 2026 - marketscreener.com
Gossamer Bio Appoints Greg Ciongoli to Board of Directors - Yahoo Finance
Gossamer Bio Inc to discuss its business update Transcript - GuruFocus
Gossamer Bio Inc (FRA:4GB0) Stock Price & 30 Year Financial Data - GuruFocus
Gossamer Bio (FRA:4GB0) PensionAndRetirementBenefit : €0.00 Mil (As of Jun. 2026) - GuruFocus
Gossamer Bio (FRA:4GB0) Net Issuance of Debt : €0.00 Mil (TTM As of Jun. 2026) - GuruFocus
Gossamer Bio Inc (FRA:4GB0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 8K Gossamer Bio Inc For: 11 September By Investing.com - Investing.com Nigeria
Gossamer Bio completes 1-for-80 reverse stock split By Investing.com - Investing.com Australia
Gossamer Bio Implements 1-for-80 Reverse Stock Split to Address Nasdaq Compliance - citybiz
Finanzdaten der Gossamer Bio Inc-Aktie (GOSS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):